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Abstract Hypertension continues to be a major contribu-
tor to global morbidity and mortality, fuelled by an abun-
dance of patients with uncontrolled blood pressure despite
the multitude of pharmacological options available. This
may occur as a consequence of true resistant hyperten-
sion, through an inability to tolerate current pharmacolog-
ical therapies, or non-adherence to antihypertensive med-
ication. In recent years, there has been a rapid expansion
of device-based therapies proposed as novel non-
pharmacological approaches to treating resistant hyperten-
sion. In this review, we discuss seven novel devices—
renal nerve denervation, baroreflex activation therapy, ca-
rotid body ablation, central iliac arteriovenous anastomo-
sis, deep brain stimulation, median nerve stimulation, and
vagal nerve stimulation. We highlight how the devices
differ, the varying degrees of evidence available to date
and upcoming trials. This review also considers the pos-
sible factors that may enable appropriate device selection
for different hypertension phenotypes.
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AV Arteriovenous
BAT Baroreflex activation therapy
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COPD Chronic obstructive pulmonary disease
DBS Deep brain stimulation
eGFR Estimated glomerular filtration rate
RCT Randomised controlled trial
RF Radiofrequency
RHTN Resistant hypertension
SNS Sympathetic nervous system
SSAHT Standardised stepped-care antihypertensive
treatment
SVR Systemic vascular resistance
US Ultrasound
VNS Vagus nerve stimulation
This article is part of the Topical Collection onDevice-Based Approaches
for Hypertension










1 Barts BPCentre of Excellence, Barts Heart Centre, St Bartholomew’s
Hospital, W Smithfield, London EC1A 7BE, UK
2 Barts NIHRCardiovascular Biomedical ResearchUnit, Charterhouse
Square, William Harvey Research Institute, Queen Mary University
London, London EC1M 6BQ, UK
3 Department of Internal Medicine, Cardiology, Angiology, Intensive
Care Medicine, Saarland University Hospital, Homburg/
Saar, Germany
4 Department of Cardiovascular Medicine, Hypertension and Heart
Failure Unit, Health Innovation Lab (Hi-Lab) Clinique Pasteur,
Toulouse, France
Curr Hypertens Rep (2016) 18: 61
DOI 10.1007/s11906-016-0670-5
# The Author(s) 2016. This article is published with open access at Springerlink.com
Introduction
Resistant hypertension (RHTN) continues to significantly
contribute to the overall population’s cardiovascular morbidi-
ty and mortality [1]. Depending on the cohort assessed, the
prevalence of RHTN is reported to range between 8 and 18 %
[1, 2, 3•]. There are many aetiologies to RHTN, and the role of
non-adherence to medications should not be understated [4].
This is often attributed to adverse drug effects, lifelong treat-
ment for an asymptomatic disease and patient factors such as
difficulty accommodating medications into activities of daily
living. As a result, up to 50 % of newly diagnosed hyperten-
sives are no longer taking their antihypertensive medications
6 months following initial prescription, and up to one quarter
of patients with RHTN are not taking any of their antihyper-
tensive drugs [5, 6].
Whilst many patients seem to express a preference for non-
drug approaches tomanaging long-term conditions, historical-
ly the options for interventional treatments have been limited.
However, the recent past has seen the introduction of a
burgeoning array of device-based therapies for hypertension
offering a more targeted approach to blood pressure (BP) low-
ering. In this review, we discuss seven novel device therapies,
all at different stages of development and with varying degrees
of evidence available to date. We highlight how they differ
and consider potential factors that may enable appropriate
device selection for different hypertension phenotypes.
Renal Denervation
Mechanism of Action
Of the novel device-based therapies for hypertension, renal
denervation (RDN) has accumulated the largest body of evi-
dence thus far. Current endovascular catheter systems typical-
ly access the renal arteries via the femoral artery and deliver
radiofrequency (RF) or ultrasound (US) energy resulting in
focal frictional heating of the arterial wall [7]. Other devices
use neurotoxic agents such as alcohol or guanethedine [8].
This causes the destruction of the peri-arterial adventitial af-
ferent and efferent renal nerves. The loss of sympathetic effer-
ent nerve signalling may lead to decreased renin secretion by
the juxtaglomerular apparatus, renal vasodilatation and sodi-
um excretion [9]. Furthermore, removal of renal afferent nerve
activity could also reduce sympathetic outflow from the cen-
tral nervous system [10]. As the energy is delivered in an
indiscriminate manner, including to the structures adjacent to
the target nerves, damage to the endothelium and the tunica
media has been observed in a porcine model [11]. It is this
collateral damage that may contribute to adverse events as
discussed below.
Current Evidence
The first proof-of-concept open-label study, SYMPLICITY
HTN-1, demonstrated that unipolar RF RDN was associated
with a mean reduction in office BP of 22/10 mmHg [12•].
Subsequently, SYMPLICITY HTN-2 was a randomised
open-labelled study, with the control group maintained on
previous medical therapy for the first 6 months before being
offered delayed RDN. There was a marked difference between
the two groups at 6 months, with better office BP control by
33/11 mmHg in favour of RDN [13]. However, the fall in
ambulatory BP levels was less impressive (11/7 mmHg) with
the caveat that these measurements were available in only half
the patients. Nonetheless, the beneficial impact appeared long-
lasting, with a fall of 33/14 mmHg observed at 36 months
post-procedure [14]. Over the 3-year follow-up period, there
were only a small number of reported procedural complica-
tions, including one haematoma and one renal artery dissec-
tion arising from 52 interventions.
Up to 2014, studies of RDN have all been open-label, and
thus criticised over the fact that a substantial placebo effect of
device therapy may have arisen, particularly due to the inva-
sive nature of the therapy which is associated with patient
discomfort [15]. In early 2014, the first randomised sham-
controlled trial of RDN, SYMPLICITY HTN-3, reported re-
sults that were less promising than the open-labelled trials. At
6 months, those who received RDN showed a reduction in
office BP of 14/7 mmHg, which was comparable to the 12/
5 mmHg drop in the sham (renal angiography only) group.
There was also a lack of difference between the groups for
ambulatory BP recordings [16••]. Whilst this was a disap-
pointing finding for proponents of RDN, potential con-
founders that have been put forward to account for the nega-
tive results include the large proportion (40 %) of participants
in both arms undergoing medication changes, and the surpris-
ing finding that only a small fraction (5 %) of patients under-
going RDN received per-protocol bilateral circumferential re-
nal nerve ablation. When considering those that did receive
per-protocol treatment, this subgroup exhibited the greatest
reductions in office, home and ambulatory systolic BP (−24,
−9, and −10 mmHg, respectively) but not reaching statistical
significance in this subgroup post hoc analysis [17].
The importance of specialist centres involved in both
selecting patients for RDN and delivering the therapy itself
may be highlighted in the DENERHTN trial. This open-label
randomised controlled trial recruited from 15 French specialist
tertiary hypertension care centres, demonstrated that in a well-
selected cohort, RDN in addition to a standardised stepped-
care antihypertensive treatment (SSAHT) resulted in a SBP
that was 5.9 mmHg lower than that in the control SSAHT
group [18].
Although the sham-controlled clinical trial data has not
been the most encouraging, registry data has been more
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heartening. The prospective Global SYMPLICITY Registry
showed that in 998 patients, RDN resulted in a reduction in
office and ambulatory systolic BP of 11.6 and 6.6 mmHg,
respectively, at 6 months [19]. The single-centre ALSTER
[20] and Heidelberg [21] registries also showed response rates
of 76 and 73 %, as defined by reductions of systolic blood
pressure ≥10 mmHg, respectively. The most recent collection
of RDN experience within the UK recently identified 253
patients across 18 specialist hypertension centres where there
was a mean fall in office and ambulatory BP of 22/9 and 12/
7 mmHg, respectively [22]. Unsurprisingly, the fall in BP was
the greatest in the highest quartile for baseline ambulatory
systolic BP (mean 199 mmHg), where the decline in office
and ambulatory BP was 30/12 and 22/13 mmHg, respectively.
Although there were multiple medications changes, more an-
tihypertensive drugs stopped (0.91/patient) as compared to
started (0.36/patient), with similar numbers where doses were
up-titrated (0.21/patient) and down-titrated (0.17/patient).
Taken together, these real-world datasets support the efficacy
of RDN and suggest the need for additional trial data.
The clinical trials to date demonstrate that RDN is a rela-
tively safe procedure with a major adverse event rate of about
1.4 % [16••]. However, it has been demonstrated using optical
coherence tomography that radiofrequency denervation may
result in diffuse arterial constriction, oedema and thrombus
formation which could form a substrate for future renovascu-
lar disorder [23]. On the other hand, both balloon-based and
non-balloon-based technologies result in different patterns of
thermal injury, including dissection and thrombus formation,
the long-term consequences of which are unknown [24]. As
the first-generation studies were conducted in 2009, the lon-
gest follow-up data thus far spans only 6 years. The unknown
long-term impact of catheter-based RDN therapy upon reno-
vascular integrity mandates future surveillance.
Although there are more studies in RDN compared to the
other device-based hypertension therapies, most studies of
RDN were limited by insufficient sample sizes, unregulated
in-trial changes in medications, infrequent use of sham con-
trol, lack of appropriate blinding, unknown procedural success
and limited involvement of hypertension specialists [25].
These inadequacies will be addressed in future trials of RDN
following consensus amongst international experts [3•, 26].
Future Directions
It is worth recalling that the technical approaches to RDN are
constantly in evolution. It is likely that different iterations of
the technology will be associated with different technical suc-
cess and complication rates. There is an increasing utilisation
of multi-electrode catheters for RF ablation and irrigated bal-
loon catheters for US ablation [8]. Alternatively, catheters are
being developed to introduce microinjection of neurotoxin
(e.g. alcohol) to chemically ablate renal nerves, which has
the theoretical advantage of facilitating deeper nerve injury
whilst avoiding damage to the endothelium and intimal layers
[27]. There is also a drive towards non-vascular techniques to
achieve RDN. An alternative method of delivering RDN, via a
transurethral approach to ablate the richly innervated renal
pelvis, is now available for patients with bleeding disorders
or renal artery anatomy that is unsuitable for current
endovascular ablation catheters [28]. A wholly non-invasive
system is also being developed by Kona Medical (Surround
Sound™) which delivers focused ultrasound targeting the dis-
tal renal artery and bifurcation using advanced Doppler imag-
ing. This system is currently being evaluated in a double blind
sham-controlled clinical trial for patients with RHTN, with an




Baroreflex activation therapy (BAT) is predicated upon the
role of arterial baroreceptors in detecting carotid sinus and
aortic arch distension in response to rises in arterial BP during
systole, which then reflexively sends afferent nerve impulses
into the nucleus tractus solitarius in the central nervous sys-
tem. This in turn decreases the efferent sympathetic nervous
system (SNS) discharge to the heart, peripheral vasculature
and kidneys, resulting in negative inotropy, vasodilatation
and reduced renin secretion, respectively. This also results in
increased parasympathetic outflow with associated reduction
in heart rate [29, 30]. Although the initial studies were con-
ducted with bilateral placement of electrodes, the current iter-
ation of this technology utilises a unilateral unipolar electrode
which is surgically attached to the right carotid sinus, with the
implantable pulse generator positioned subcutaneously in the
subclavian area. The hardware and surgical technique has pro-
gressively evolved so that it is now feasible to be implanted
under conscious sedation.
Current Evidence
The first-generation Rheos™ device (requiring bilateral elec-
trode placement) was initially evaluated in a feasibility study.
In the non-randomised DEBuT-HT open-label trial with no
comparator arm, implantation of the device in 45 patients with
RHTN resulted in an average BP reduction of 21/12 mmHg at
3 months and 33/22 mmHg at 2 years [31]. In a separate small
open-label study of 21 patients with RHTN there was a reduc-
tion of office BP by 31/14 mmHg and heart rate by 5 beats/
min following BATwith the Rheos device [32]. This led to the
subsequent Rheos Pivotal Trial: 265 patients were randomised
in a 2:1 fashion to early (1 month post-implantation) or
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delayed (6 months post-implantation) device activation. The
trial did not meet the endpoints for acute responders or proce-
dural safety. Although there was no significant difference in
the primary efficacy end point of ≥10 mmHg drop in systolic
BP after 6-month follow-up, 42 % of participants in the early
group vs 24 % of the delayed group achieved systolic BP
<140 mmHg. Notably, the pivotal study also reported patients
developing transient (4.4%) or permanent (4.8%) facial nerve
injury [33]. Longer-term follow-up of this study reported that
systolic BP reductions of 30 mmHg were sustained at
53 months [34]. A recent subgroup analysis of this trial indi-
cated that unilateral therapy was more effective than bilateral
therapy, and further sub-stratification suggests that right-sided
stimulation may be more effective than left [35]. This may
have important implications for future studies and clinical
practice, as implanting a single lead could result in less
procedure-related adverse events.
The next-generation update of this technology, Barostim
neo™ system, utilises a smaller longer lasting generator and
single lead carotid sinus stimulation [36]. A preliminary study
in 33 patients with RHTN demonstrated BP reductions of 26/
12 mmHg at 6 months with baseline systolic BP ≥160 mmHg.
Importantly, the new technology allowed for shorter implan-
tation and hospitalisation times, with less immediate
procedure-related complications compared to the first genera-
tion system and no reports of either temporary or permanent
facial nerve injury [37•].
BAT also appeared to be effective in the setting of chronic
kidney disease (eGFR <90 mL/min/1.73 m2 or proteinuria).
After 6 months, 23 patients managed with the Barostim neo™
system demonstrated a 17/9 mmHg fall in BP as compared to
the 1/1 mmHg fall in the 21 patients in the control group
(standard medical management), and a lower heart rate
(−5 beats/min) [38].
Future Directions
The Barostim Hypertension Pivotal Trial (clinicaltrials.gov:
NCT01679132) is currently in progress and aims to enrol
310 patients with RHTN randomised to receiving optimal
medical management alone or in combination with the baro-
reflex activation therapy. BAT may also have a role outside of
BP management and is currently being evaluated as an ad-
junctive therapy in heart failure [39].
Carotid Body Ablation
Mechanism of Action
Carotid bodies are peripheral chemoreceptors that regulate
sympathetic toneand respiratoryminuteventilation in response
to stimuli such as hypoxia, hypercapnia, hypoglycaemia, and
acidosis. The ablation of carotid body (CB) function has been
proposed as a target for circulatory regulation as increased ef-
ferent signalling fromCBs is associatedwith hypertension that
is reversible when the signalling is downregulated [40].
Current Evidence
In COPD patients undergoing bilateral CB resection, systolic
BP was reduced by 40 mmHg at 6 months post-operatively in
a hypertensive sub-group, despite no long-term improvement
in ventilatory parameters [41]. A recent proof of concept study
of unilateral CB ablation as therapy for RHTN has demon-
strated sustained office BP reduction of 23/12 mmHg at
6 months post-operatively in 8 out of 15 patients who had
evidence of increased baseline CB activity. There were no
serious adverse events reported, and hypoxic ventilatory drive
was maintained [42].
Future Directions
An ongoing uncontrolled observational study will assess the
feasibility of unilateral endovascular CB ablation in a larger
cohort of patients with RHTN. The targeted trial enrolment is
set at 50 patients and is expected to report its findings in early
2017 (clinicaltrials.gov: NCT02099851). A separate trial in
patients with RHTN aims to assess the effect of CB de-
afferentation achieved by local US-guided infiltration of lido-
caine followed by electrical stimulation (clinicaltrials.gov:
NCT02519868). No prospective sham-controlled clinical tri-
als have been registered to date.
Central Iliac Arterio-Venous Anastomosis
Mechanism of Action
In cont ras t to the above devices tha t a im to be
sympathomodulatory, a central iliac arterio-venous (AV) anas-
tomosis intends to reduce effective arterial volume, systemic
vascular resistance (SVR) and cardiac afterload, thus lowering
BP. This is achieved by creating a 4-mm fixed calibre conduit
between the proximal arterial and low resistance venous circu-
lation, typically the external iliac artery andvein, using a nitinol
stent-like device (ROXAV coupler) placed under fluoroscopic
guidance [43].Thisdiverts a calibratedamountof arterial blood
(0.8 to 1.0 L/min) into the proximal large capacitance venous
circuit, helping restore the Windkessel function of the central
circulation, which may be of particular benefit in patients with
greatly reduced vascular compliance due to arterial stiffening.
The opening of the anastomosis results in an immediate and
significant reduction of SVR and BP. The immediacy of the
BP improvement suggests a negligible contribution from
placebo/Hawthorne effects. It should be noted that whilst the
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primary physiological mechanism may be related to reduction
in effec t ive a r te r ia l vo lume, the device may be
sympathomodulatory through increasing venous oxygenation
and increasing right heart stretch through increased pre-load
[44, 45].
Current Evidence
Formation of a central iliac AVanastomosis was initially stud-
ied in patients with COPD with the intention of improving
exercise capacity [46]. Subsequently, in an open-label study
of 24 patients with COPD and mild hypertension, central iliac
AVanastomosis was associated with an improvement in oxy-
gen delivery and mixed venous oxygen saturations. There was
an observed reduction in office BP from 145/86 to 132/
67 mmHg at 12 months, without changes in medications [47].
The first investigation into centralAVanastomoses inhyper-
tension was the randomised controlled, open-label, ROX
CONTROL HTN trial [48••], in which 83 patients were
randomised to either standard care or insertion of AV coupler
in addition to standard care. At 6 months, office BP and ambu-
latoryBPwere reduced by27/20 and 14/14mmHg, respective-
ly, in the coupler group whilst no significant changes were ob-
served in the control group. There was also a reduction in
hospitalisations for hypertensive urgencies in the coupler
group. Whilst there were no significant differences in the use
of medications at baseline between the groups, in the coupler
group 25%of patients decreased their antihypertensiveswhilst
30 % of the control group had an increase in medications.
Modified intention to treat analysis of theBPchangesmayhave
masked the true extent of coupler-inducedBP reduction [48••].
The main complication reported in the coupler group was a
29 % incidence of ipsilateral venous stenosis which was suc-
cessfully managed by venoplasty and/or stenting. In a small
subset of patients who had failed to respond to prior RDN,
centralAVanastomosis resulted in significant reduction in both
the office BP (34/22 mmHg) and ambulatory BP (12/
15 mmHg). This may suggest that AV coupler therapy may be
beneficial in cases where sympathomodulation has failed [49].
Future Directions
Early clinical experience with the coupler suggest that this
novel approach which addresses mechanical aspects of the
circulation has promise, but more long-term safety and effica-
cy data are clearly required. Requirement for an appropriate
sham-controlled study may be confounded by spontaneous
patient reporting of a palpable thrill at the site of the AVanas-
tomosis. Presently, ongoing evaluation of the therapy is taking
place within a global registry study (clinicaltrials.gov:
NCT1885390) and a US pivotal study is in the pipeline.
Deep Brain Stimulation
Mechanism of Action
The role of specific sub-structures within the brain in modu-
lating autonomic activity for cardiovascular reflexes has pre-
viously been indicated in animal studies. The stimulation of
the periaqueductal gray region of cats and rats has been shown
to be linked to changes in blood pressure, heart rate and va-
sodilatation [50, 51].
Current Evidence
To date, there is minimal data regarding the use of deep brain
stimulation (DBS) as a treatment for hypertension. An initial de-
scriptionofDBSdemonstratingbenefit inrefractoryhypertension
was based on targeted stimulation of the venterolateral
periaquductal grey/periventricular grey for analgesia in stroke-
associatedhemibodycentralpainsyndrome.Theobservedreduc-
tion in blood pressure of up to 33/13 mmHg appears to be inde-
pendent of any analgesic effects, as it persisted even when pain
levels returned to pre-surgical levels after several months [52].
The suggested mechanismmay be via vasodilatation and reduc-
ing total peripheral resistance [53]. In a larger cohort of patients,
utilizingDBSfor chronicneuropathicpainorParkinson’sdisease
resulted in improved vasomotor baroreflex sensitivity, decreased
muscle sympathetic nerve activity and reduction in BP [54]. In
commonwith other device therapies for hypertension, there also
appears to be a range of BP responses to the therapy,where some
could even be regarded as non-responders.
Future Directions
Thus far, there are no registered trials ofDBS as a device-based
therapy for hypertension, although BP responses to DBS are
being evaluated in an on-going studywherein the primary indi-
cation is for relief of chronic neuropathic pain in patients with
spinal cord injury (clinicaltrials.gov: NCT02006433).
Median Nerve Stimulator
Mechanism of Action
A novel implantable non-constant neurostimulator has been de-
signed byValencia Technologies (eCoin) to be small enough, ap-
proximately 2 cm in diameter, to be placed subcutaneously over-
lying the median nerve as a potential therapy for RHTN.Median
nerve stimulation, albeit by a different electroacupuncture system,
is already supported by limited data. In anaesthetised male rats,
delivery of electroacupuncture at points overlying the median
nerve reduced the sympathoexcitatory BP response to gastric dis-
tension [55]. This BP-lowering effect of electroacupuncture over
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Although there are yet to be any peer-reviewed data for me-
dian nerve stimulation as a device-based therapy for RHTN,
Valencia Technologies has indicated that their unpublished
interim results showed the treatment group having a net
change in systolic BP of 16.7 mmHg lower than that of the
sham (implanted device but not activated) group
(http://valenciatechnologies.com/first-application).
Future Directions
An ongoing clinical trial aims to recruit 102 patients with




Whilst there have been significant efforts in creating devices
that modulate the SNS at various points, the parasympathetic
nervous system has been largely neglected. The vagus nerve,
together with the thoracic ganglia, is the principle source of
parasympathetic innervationof theheartwith resultantnegative
inotropic and chronotropic effects.
Vagal nerve stimulation (VNS) in Dahl salt-sensitive rats
attenuated salt-induced hypertension and arrhythmias as com-
pared to rats that had sham surgery [57]. On its own, VNSwas
able to reduce BP without inducing bradypnoea or bradycar-
dia, which may be anticipated as a side effect of vagal stimu-
lation [58], but stimulation-induced apnoea was observed fol-
lowing selective VNS in combination with beta-blockers [59].
Notably, the BP-lowering effect of VNS is partially additive to
the effects of intravenous metoprolol [59] or enalapril [60].
Current Evidence
Limited experience of the impact of VNS on blood pressure
comes from a report of two patients undergoing carotid end-
arterectomy and coronary bypass surgery. Stimulating the
vagus nerve resulted in a current- and frequency-dependent
lowering of systolic BP and heart rate. It is important to rec-
ognise that episodes of atrio-ventricular block and ventricular
asystole were observed at higher current and frequency, but
were reversible upon termination of VNS [61].
Future Directions
A study of selective VNS in patients undergoing carotid end-
arterectomy and coronary artery bypass grafting, with four
patients enrolled, has been completed, but the results have
not yet been published (clinicaltrials.gov: NCT00983632).
Can Focused Patient Selection Improve Outcomes
When Using Device Therapies of Hypertension?
Variations in responses to antihypertensive drug therapy across
thepopulationhavebeenwelldescribed. Itwouldbereasonable
to hypothesise that the device-based therapies discussed here,
each targeting unique pathophysiological pathways, would
have their respective determinants of responders and non-
responders. It has been long established that renal norepineph-
rine spillover is negatively correlatedwith age [62], suggesting
that sympathomodulatory devices may be more efficacious in
the younger adult, whereas devices that targets mechanisms
other than sympathetic drive may be better suited to treating
hypertension in the older adult.
The heterogeneity of BP responses to RDN suggests that it
might be effective in a select group of patients, as subgroup
analyses suggest a better response in non-African Americans
as well as in younger patients and those with preserved renal
function [63•]. This supports the hypothesis that younger pa-
tients with higher sympathetic tone and preserved vascular
compliance may respond better to RDN. Conversely patients
with isolated systolic hypertension and the associated struc-
tural hypertension may not be optimal candidates for RDN
[64]. This interpretation may also extend to other
sympathomodulatory aproaches such as BAT and CB abla-
tion, but data is limited with these procedures. It has already
been noted that assessment of baseline CB activity may be
useful for selecting optimal responders to CB ablation [42].
Conversely, it may it might be hypothesised that a technique
that is based on reducing effective arterial volume such as
central AVanastomosis may be more appropriate in hyperten-
sive patients with reduced vascular compliance and less dom-
inated by elevated sympathetic tone. There is minimal data
concerning median nerve and vagal nerve stimulation, which
limits our ability to identify a subgroup of patients that may be
responders to these technologies. Tests that would allow to
identify patients with high likelihood of response to various
device-based therapies are urgently needed as they will help to
prevent patients from risks related to unnecessary procedures.
Conclusions
Here, we have discussed seven different device-based thera-
pies for hypertension (summarised in Table 1), with limited
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evidence of efficacy. Additionally, long-term data, including
that of procedure- and device-related adverse events, is still to
be determined. A consistent and ongoing challenge is the de-
sign and execution of rigorous, appropriately controlled stud-
ies with blinded endpoints. With that caveat, these technolo-
gies should all still be considered to be experimental therapeu-
tic options for which there are insufficient data to presently
support their use in routine clinical practice. In an ideal future,
given the high costs of these technologies and the fact that
there may be need for multiple treatments/battery replacement
for some devices, there should be an algorithm to allow
individualised treatment selection best suited for the patient’s
hypertension phenotype. Furthermore, whilst device-based
therapy is currently being explored predominantly for
RHTN, it may be increasingly relevant to patients with mul-
tiple medications intolerances or those who simply wish to
avoid long-term drug therapy.
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